Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan vs somatropin in pediatric growth hormone deficiency (China)
CTR20211271Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of somapacitan in growth hormone deficiency (GHD), sponsored by Novo Nordisk. Started Jun 2021; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20211271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211271.